Variables | Total subject | BMI <23 kg/m2 | BMI 23–24.9 kg/m2 | BMI ≥25 kg/m2 | P valuea |
---|---|---|---|---|---|
No. of patients (%) | 211 | 75(35.5) | 71(33.6) | 65(30.8) | |
BMI (kg/m2) | <0.001 | ||||
Median (IQR) | 23.9(3.4) | 21.4(2.2) | 24.2(1.1) | 26.4(1.9) | |
Range | 16.1–30.1 | 16.1–22.9 | 23.0–24.9 | 25.0–30.1 | |
Age (years) | 0.373 | ||||
Median (IQR) | 68(8) | 67(11) | 70(9) | 67(8) | |
Range | 47–86 | 48–86 | 56–83 | 47–81 | |
Preoperative PSA (ng/ml) | 0.607 | ||||
Median (IQR) | 13.4(11.9) | 13.5(15.0) | 14(10.3) | 11.5(13.1) | |
Range | 1.4–293.3 | 1.7–293.3 | 1.4–62.5 | 2.3–85.6 | |
Prostate volume (ml) | 0.326 | ||||
Median (IQR) | 36(16) | 37(13) | 36(17) | 35.5(18) | |
Range | 12–98 | 13–89 | 19–98 | 12–91 | |
Positive DRE finding (%) | 68(67.6) | 23(31.1) | 24(33.8) | 21(32.3) | 0.94 |
TRUS nodule (%) | 106(50.7) | 31(41.9) | 44(62.0) | 31(48.4) | 0.049 |
Clinical stageb (%) | 0.156 | ||||
cT1 | 100(47.8) | 41(55.4) | 28(39.4) | 31(48.4) | |
≥cT2 | 109(52.2) | 33(44.6) | 43(60.6) | 33(51.6) | |
Biopsy GS (%) | 0.222 | ||||
≤6 | 82(38.9) | 35(46.7) | 25(35.3) | 22(33.8) | |
≥7 | 129(61.1) | 40(53.3) | 46(64.8) | 43(66.2) | |
Pathological GS (%) | 0.303 | ||||
≤6 | 65(30.8) | 28(37.3) | 20(28.2) | 17(26.2) | |
≥7 | 146(69.2) | 47(62.7) | 51(71.8) | 48(73.8) | |
Positive surgical margin (%) | 26(12.3) | 9(12.0) | 4(5.6) | 13(20.0) | 0.039 |
Extra capsular invasion (%) | 31(14.7) | 13(17.3) | 8(11.3) | 10(15.4) | 0.575 |
Seminal vesicle invasion (%) | 24(11.4) | 13(17.3) | 4(5.6) | 7(10.8) | 0.083 |
Lymph node invasion (%) | 5(2.4) | 2(2.7) | 1(1.4) | 2(3.1) | 0.797 |